You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases
|
|---|---|
| Published in |
BMC Cancer, March 2018
|
| DOI | 10.1186/s12885-018-4191-2 |
| Pubmed ID | |
| Authors |
N. Andratschke, H. Alheid, M. Allgäuer, G. Becker, O. Blanck, J. Boda-Heggemann, T. Brunner, M. Duma, S. Gerum, M. Guckenberger, G. Hildebrandt, R. J. Klement, V. Lewitzki, C. Ostheimer, A. Papachristofilou, C. Petersen, T. Schneider, R. Semrau, S. Wachter, D. Habermehl |
| Abstract |
The intent of this pooled analysis as part of the German society for radiation oncology (DEGRO) stereotactic body radiotherapy (SBRT) initiative was to analyze the patterns of care of SBRT for liver oligometastases and to derive factors influencing treated metastases control and overall survival in a large patient cohort. From 17 German and Swiss centers, data on all patients treated for liver oligometastases with SBRT since its introduction in 1997 has been collected and entered into a centralized database. In addition to patient and tumor characteristics, data on immobilization, image guidance and motion management as well as dose prescription and fractionation has been gathered. Besides dose response and survival statistics, time trends of the aforementioned variables have been investigated. In total, 474 patients with 623 liver oligometastases (median 1 lesion/patient; range 1–4) have been collected from 1997 until 2015. Predominant histologies were colorectal cancer (n = 213 pts.; 300 lesions) and breast cancer (n = 57; 81 lesions). All centers employed an SBRT specific setup. Initially, stereotactic coordinates and CT simulation were used for treatment set-up (55%), but eventually were replaced by CBCT guidance (28%) or more recently robotic tracking (17%). High variance in fraction (fx) number (median 1 fx; range 1–13) and dose per fraction (median: 18.5 Gy; range 3–37.5 Gy) was observed, although median BED remained consistently high after an initial learning curve. Median follow-up time was 15 months; median overall survival after SBRT was 24 months. One- and 2-year treated metastases control rate of treated lesions was 77% and 64%; if maximum isocenter biological equivalent dose (BED) was greater than 150 Gy EQD2Gy, it increased to 83% and 70%, respectively. Besides radiation dose colorectal and breast histology and motion management methods were associated with improved treated metastases control. After an initial learning curve with regards to total cumulative doses, consistently high biologically effective doses have been employed translating into high local tumor control at 1 and 2 years. The true impact of histology and motion management method on treated metastases control deserve deeper analysis. Overall survival is mainly influenced by histology and metastatic tumor burden. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 132 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 132 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 28 | 21% |
| Other | 15 | 11% |
| Student > Ph. D. Student | 13 | 10% |
| Student > Master | 13 | 10% |
| Student > Bachelor | 11 | 8% |
| Other | 23 | 17% |
| Unknown | 29 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 64 | 48% |
| Biochemistry, Genetics and Molecular Biology | 3 | 2% |
| Computer Science | 3 | 2% |
| Nursing and Health Professions | 3 | 2% |
| Immunology and Microbiology | 3 | 2% |
| Other | 11 | 8% |
| Unknown | 45 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 May 2022.
All research outputs
#3,996,427
of 22,925,760 outputs
Outputs from BMC Cancer
#950
of 8,333 outputs
Outputs of similar age
#79,995
of 333,074 outputs
Outputs of similar age from BMC Cancer
#39
of 232 outputs
Altmetric has tracked 22,925,760 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,333 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 333,074 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 232 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.